Gelder Mark S. MD 4
4 · Onconova Therapeutics, Inc. · Filed Aug 4, 2022
Insider Transaction Report
Form 4
Gelder Mark S. MD
Chief Medical Officer
Transactions
- Exercise/Conversion
Common Stock
2022-08-02+4,650→ 7,031 total - Tax Payment
Common Stock
2022-08-03$1.32/sh−1,135$1,498→ 5,896 total - Exercise/Conversion
Restricted Stock Units
2022-08-02−4,650→ 9,300 total→ Common Stock (4,650 underlying)
Footnotes (2)
- [F1]Restricted stock units convert into common stock on a one-for-one basis.
- [F2]On August 2, 2021 the reporting person was granted 13,950 restricted stock units which vest over 3 years from the date of grant: 33% on the first anniversary; 33% on the second anniversary; and 34 % on the third anniversary.